Efficacy and Safety Profile of Different Schedules of Adjuvant Trastuzumab Therapy among Patients with HER2-Positive Breast Cancer: Real-World Experience from a Tertiary Cancer Center in South India
One year of adjuvant trastuzumab is the standard of care for HER2-positive breast cancer. In low–middle income countries, delivery of 1-year trastuzumab is challenging due to significant financial burden. Evidence for shorter durations of adjuvant trastuzumab is gaining popularity in this regard. In...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2025-01-01
|
| 叢編: | South Asian Journal of Cancer |
| 主題: | |
| 在線閱讀: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1791969 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|